# Subjective and objective results 1 year after robotic sacrocolpopexy using a lightweight Y-mesh

**Authors:** Patrick J. Culligan, Emil Gurshumov, Christa Lewis, Jennifer L. Priestley, Jodie Komar, Nihar Shah, Charbel G. Salamon

PMC · DOI: 10.1007/s00192-013-2265-x · 2013-11-22

## TL;DR

This study shows that robotic sacrocolpopexy with a lightweight Y-mesh provides excellent results in treating pelvic organ prolapse one year after surgery.

## Contribution

The study evaluates the 12-month outcomes of a specific lightweight Y-mesh in robotic sacrocolpopexy.

## Key findings

- Clinical cure rate was 95% at 12 months.
- Objective anatomic cure rate was 84% at 12 months.
- Significant improvement in patient-reported outcomes like PFDI-20 and PFIQ-7 scores.

## Abstract

The objective of this study was to assess outcomes following robotic sacrocolpopexy using a lightweight polypropylene Y-mesh.

During our study period, all patients who underwent robotic sacrocolpopexy were enrolled in this single-arm prospective trial. Endpoints included Pelvic Organ Prolapse Quantification (POP-Q) values; Pelvic Floor Distress Inventory, short form 20 (PFDI-20); Pelvic Floor Impact Questionnaire, short form 7 (PFIQ-7); Surgical Satisfaction scores; and the Sandvik Incontinence Severity Index. All surgeries were performed with a pre-configured monofilament type 1 polypropylene Y-mesh (Alyte©, C.R. Bard, Covington, GA, USA). Cure rates at 12 months were calculated using two separate definitions: (1) “clinical cure”: no POP-Q points > 0, point C ≤ −5, no prolapse symptoms on the PFDI-20, and no reoperations for prolapse and (2) “objective anatomic cure”: POP-Q stage 0 or 1, point C of ≤ −5, and no reoperations for prolapse.

A total of 150 patients underwent robotic sacrocolpopexy and 143 (95 %) were available for 12-month follow-up. Mean age was 58.6 ± 9.8 and mean body mass index was 26.3 ± 4.5. Mean operative time and blood loss were 148 ± 27.6 min (range 75–250 min) and 51.2 ± 32, respectively. There were no mesh erosions or exposures, and mesh edges were not palpable in any patient. At 12 months the clinical cure rate was 95 %, and the objective anatomic cure rate was 84 %. The PFDI-20 mean score improved from 98 at baseline to 17 at 12 months (p < 0.0001); PFIQ-7 scores improved from 59 to 6.5 (p < 0.0001).

Robotic sacrocolpopexy using this lightweight polypropylene Y-mesh offers excellent subjective and objective results at 1 year.

## Linked entities

- **Diseases:** pelvic organ prolapse (MONDO:0000082)

## Full-text entities

- **Genes:** GGH (gamma-glutamyl hydrolase) [NCBI Gene 8836] {aka GATD10, GH}
- **Diseases:** stress incontinence (MESH:D014550), erosion (MESH:D014077), dyspareunia (MESH:D004414), POP (MESH:D056887), Incontinence (MESH:D014549), voiding dysfunction (MESH:C537271), pain (MESH:D010146), postmenopausal bleeding (MESH:D006470), prolapse (MESH:D011391), vaginal bulge (MESH:D014627), visceral injuries (MESH:D007418)
- **Chemicals:** Gore-Tex (MESH:D011138), Ba (MESH:D001464), PB (MESH:D007854), GH (-), Bp (MESH:C038809), polypropylene (MESH:D011126), polyester (MESH:D011091)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC4544463/full.md

---
Source: https://tomesphere.com/paper/PMC4544463